Overview

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.
Phase:
Phase 1
Details
Lead Sponsor:
BioNTech Research & Development, Inc.
Treatments:
Folfirinox